---
title: "The Brazilian Bridge: How Polylaminin is Rewiring Spinal Cord Repair"
pubDate: 2026-02-15
pdfUrl: "https://assets.beyondparalysis.uk/UFRJ%20Polylaminin%20Regenerative%20drug.pdf"
youtubeUrl: "https://youtu.be/GzQmaBCJVcs"
executiveSummary: "A landmark biological breakthrough from Brazil utilizing a specialized protein mesh derived from human placentas to physically bridge spinal cord injury gaps. With a 75% motor recovery rate in academic pilots, this therapy has officially moved into formal Phase 1 clinical trials as of January 2026."
---

## The History
The story of Polylaminin is a 30-year journey of "scientific persistence" led by Professor Tatiana Coelho-Sampaio at the Federal University of Rio de Janeiro (UFRJ). It began with a fundamental question: Why do nerves regrow in a developing embryo but fail in an adult spinal cord? The answer lay in **Laminin**, a protein that guides nerve growth. While ordinary laminin clumps together in the body, the UFRJ team discovered that by using a specific acidic pH process in the lab, they could "knit" the protein into a stable, microscopic mesh called **Polylaminin**. After successful outcomes in paralyzed dogs (including the famous "Fantástico" cases), the team moved into an 8-patient human pilot study, leading to the formal 2026 regulatory approval for Phase 1 trials.

## Key People
* **Prof. Tatiana Coelho-Sampaio**: The lead scientist at UFRJ and the primary architect of the polylaminin technology.
* **Dr. Marco Aurélio de Lima**: The neurosurgeon with 30+ years of experience who performed the initial human intraspinal injections.
* **Flávia Bueno**: A nutritionist and patient advocate who gained early access to the treatment via court injunction and regained significant right-arm movement.
* **Cristália Laboratories**: The Brazilian pharmaceutical partner responsible for the industrial-scale manufacturing of the drug from human placentas.

## The Story
For the SCI community, Polylaminin represents a shift from "managing" paralysis to "restoring" biology. The emotional core of this research is found in the "unprecedented" recovery seen in the first human cohort. In a field where "Complete" (AIS A) injuries rarely see spontaneous motor recovery (statistically ~15%), the fact that 6 out of 8 early participants regained voluntary movement changed the conversation in South America. The treatment offers hope that the "biological wall" created by an injury can be turned back into a "growth zone."

## Deep Dive: The Research & Mechanism
Polylaminin is a **biomimetic polymer**. Unlike stem cells, which try to replace lost tissue, Polylaminin provides the structural "scaffold" that remaining nerves need to grow across a lesion.

### Mechanism of Action
1. **The Scaffold**: When injected, Polylaminin forms a microscopic lattice. It mimics the environment of the developing nervous system, giving axons (the "wires" of the spine) a physical track to follow.
2. **Axonal Regeneration**: The mesh specifically targets the "growth cone" of a damaged nerve, encouraging it to push through the injury site rather than retreating.
3. **Glial Scar Modification**: Research suggests Polylaminin helps bypass the inhibitory environment of the glial scar, the physical barrier that normally prevents healing.

### Clinical Status (2026 Update)
* **Current Phase**: Phase 1 (Safety and Feasibility).
* **Recent Approval**: On January 5, 2026, ANVISA (Brazil’s FDA) approved the formal Phase 1 trial for 5 volunteers.
* **Eligibility**: Patients must have a **complete thoracic injury** and receive the injection within **72 hours** of trauma.
* **Pilot Results**: In the academic pilot, 75% of participants regained voluntary motor contraction. One subject even converted from "Complete" paralysis to "Incomplete" (AIS C/D) within a year.

## Sources & References
* **Folha de S.Paulo (Jan 2026):** [First stage of testing for a drug targeting complete spinal cord injury is approved in Brazil](https://www1.folha.uol.com.br/internacional/en/scienceandhealth/2026/01/first-stage-of-testing-for-a-drug-targeting-complete-spinal-cord-injury-is-approved-in-brazil.shtml)
    * *Official reporting on the ANVISA approval for the 2026 clinical trial phase.*
* **medRxiv (Feb 2024):** [Polylaminin pilot study preprint](https://www.medrxiv.org/content/10.1101/2024.02.19.24301010v1)
    * *The full academic preprint detailing the 75% recovery rate in the initial human pilot study.*
* **Frontiers in Veterinary Science (2025):** [Polylaminin in chronic canine paralysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380836/)
    * *Study showing Polylaminin's success in treating chronic paralysis in dogs when combined with neurotrophic factors.*